NeuroPace (NASDAQ:NPCE) Stock Price Down 4.4% – What’s Next?

NeuroPace, Inc. (NASDAQ:NPCE) shares fell 4.4% on Friday . The company traded as low as $16.05 and last traded at $16.2150. 57,075 shares traded hands during mid-day trading, a decline of 83% from the average session volume of 336,246 shares. The stock had previously closed at $16.96.

Analysts Set New Price Targets

A number of brokerages have recently commented on NPCE. Weiss Ratings reissued a “sell (d-)” rating on shares of NeuroPace in a report on Monday, December 29th. JPMorgan Chase & Co. increased their target price on NeuroPace from $18.00 to $20.00 and gave the company an “overweight” rating in a research note on Wednesday, December 10th. Wells Fargo & Company raised their price target on NeuroPace from $15.00 to $16.00 and gave the company an “overweight” rating in a research report on Wednesday, November 5th. UBS Group lifted their price target on NeuroPace from $18.00 to $22.00 and gave the stock a “buy” rating in a research note on Tuesday, December 16th. Finally, Leerink Partners reiterated an “outperform” rating and set a $19.00 price objective on shares of NeuroPace in a research report on Wednesday, November 5th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $18.50.

NeuroPace Price Performance

The firm’s 50 day simple moving average is $15.18 and its two-hundred day simple moving average is $11.66. The company has a debt-to-equity ratio of 3.17, a current ratio of 4.86 and a quick ratio of 3.94. The firm has a market capitalization of $557.28 million, a P/E ratio of -22.01 and a beta of 1.85.

NeuroPace (NASDAQ:NPCE) last released its quarterly earnings data on Tuesday, November 4th. The company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.09. NeuroPace had a negative return on equity of 136.60% and a negative net margin of 25.28%.The firm had revenue of $27.35 million for the quarter, compared to the consensus estimate of $24.64 million. As a group, analysts predict that NeuroPace, Inc. will post -1 earnings per share for the current year.

Institutional Trading of NeuroPace

Institutional investors have recently made changes to their positions in the stock. SG Americas Securities LLC purchased a new position in shares of NeuroPace in the fourth quarter worth $118,000. Tudor Investment Corp ET AL boosted its position in NeuroPace by 29.3% during the 3rd quarter. Tudor Investment Corp ET AL now owns 153,698 shares of the company’s stock valued at $1,585,000 after buying an additional 34,807 shares during the period. Armistice Capital LLC grew its holdings in NeuroPace by 12.6% in the 3rd quarter. Armistice Capital LLC now owns 1,298,000 shares of the company’s stock worth $13,382,000 after acquiring an additional 145,665 shares during the last quarter. PharVision Advisers LLC purchased a new position in shares of NeuroPace in the third quarter valued at about $232,000. Finally, Quarry LP increased its position in shares of NeuroPace by 94.9% in the third quarter. Quarry LP now owns 3,845 shares of the company’s stock valued at $40,000 after acquiring an additional 1,872 shares during the period. Hedge funds and other institutional investors own 78.83% of the company’s stock.

NeuroPace Company Profile

NeuroPace, Inc is a medical device company based in Mountain View, California, that develops innovative neuromodulation systems for the treatment of neurological disorders. Founded in the late 1990s out of research at Stanford University, the company’s mission centers on delivering closed-loop, “smart” therapies that monitor and respond to electrical activity in the brain. In 2020, NeuroPace completed its initial public offering and now trades on the NASDAQ under the ticker NPCE.

The company’s flagship product, the RNS® System, is an implantable device designed for adults with medically refractory focal epilepsy.